対麻痺におけるBCI（ブレインコンピュータインターフェイス）の世界市場：2024年～2031年

概要

対麻痺におけるBCI（ブレインコンピュータインターフェイス）の世界市場は、2023年に2億3,850万米ドルに達し、2031年には3億4,620万米ドルに達すると予測され、予測期間2024-2031年のCAGRは4.2%で成長する見込みです。

ブレインコンピュータインターフェイスは、脳と外部出力間の直接通信を可能にするシステムです。これらのBCIデバイスは、ニューロンの電気生理学を測定するセンサーで構成され、その情報をコンピュータ、ロボット肢、または脳信号を処理するソフトウェアを組み込んだその他の外部システムなどの外部デバイスに中継します。要するに、ブレインコンピュータインターフェイスは、ユーザーが考えることによって機器をコントロールすることを可能にします。現在、ニューロテクノロジー企業の多くが、これらの装置を臨床使用するために積極的にテストを行っています。下半身不随の患者にとって、ブレインコンピュータインターフェイスは、体を動かし、通常の仕事をこなし、生活の質全体を向上させる機会を提供すると思われます。

市場力学：

促進要因

投資と研究開発活動の増加

対麻痺患者用BCI（ブレインコンピュータインターフェイス）機器は、現在も開発中です。ニューロテック企業数社がBCIデバイスの臨床利用を目指しており、中には規制当局から人体実験の承認を得ている企業もあります。こうした取り組みが進むにつれ、同市場は最も高い成長率で成長すると予想されます。

例えば、2021年4月、IpsiHandは米国食品医薬品局（FDA）から臨床使用が承認された最初のブレインコンピュータインターフェイス製品となった。Neuroloutions社が開発したIpsiHandは、上肢慢性脳卒中患者のリハビリに適応されます。IpsiHandは自宅や診療所で使用することができます。

4月のIpsiHandの承認に続き、USFDAはBlackrock Neurotech社のMoveAgain Brain-Computer Interface System Receivesを、移動障害のある患者に使用する画期的な機器として指定しました。このBCIシステムにより、患者はコンピューター、モバイル、車椅子を操作できるようになります。

このような企業は、BCI発明の調査研究を積極的に行っています。例えば、イーロン・マスクが経営するニューリンク社は、今年初めに最初の患者にプロプリエトリーBCI装置を移植しました。PRIME研究は、麻痺のある患者を対象に、思考で外部機器を操作するための装置の安全性と機能性を評価することを目的としています。

このような画期的な技術革新は、近い将来、麻痺患者の治療に革命をもたらすと期待されています。

抑制要因

対麻痺におけるBCI（ブレインコンピュータインターフェイス）市場は、臨床使用に十分な承認製品がないこと、承認製品のコストが高いこと、開発コストが高いこと、患者層における技術の曖昧さなど、いくつかの要因によって制約を受けています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 投資と研究開発活動の増加
    • 対麻痺治療への技術導入の増加
  • 抑制要因
    • 臨床的に承認された装置の不足
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 タイプ別

• 侵襲性
• 低侵襲性
• 非侵襲性

第7章 技術別

• 微小電極アレイ（中東・アフリカ）
• 皮質脳波計（EcoG）
• 脳波計（EEG）
• 機能的近赤外分光法（fNIRS）
• その他

第8章 用途別

• 移動支援
• コミュニケーション
• リハビリテーション
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Neurolutions, Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Synchron
• Neuralink
• Blackrock Neurotech.
• BrainGate.
• Paradromics.
• Cognixion
• EMOTIV
• Precision Neuroscience
• Bitbrain Technologies

第12章 付録

Overview

The global BCI (brain-computer interfaces) in paraplegia market reached US$ 238.5 million in 2023 and is expected to reach US$ 346.2 million by 2031, growing at a CAGR of 4.2% during the forecast period 2024-2031.

Brain-computer interfaces are the systems that enable direct communication between the brain and the external output. These BCI devices consist of sensors that measure the electrophysiology of neurons and relay the information to an external device such as a computer, robotic limb, or any other external system embedded with software that processes the brain signals. In short, brain-computer interfaces allow the users to control devices by thinking. At present, many of the neurotechnology firms are actively testing these devices to bring them to clinical use. For paraplegic patients, brain-computer interfaces will provide an opportunity to move, perform regular tasks, and improve their overall quality of life.

Market Dynamics: Drivers

Rising investments and R&D activities

BCI (brain-computer interface) devices for paraplegia patients are still under development. Several neurotech companies are striving to bring BCI devices to clinical use, and some of these companies have received approval from the regulatory bodies to test on human subjects. As the efforts continue to rise, the market is anticipated to grow with the highest growth rate.

For instance, in April 2021, IpsiHand became the first brain-computer interface product to be approved for clinical use by the U.S. Food and Drug Administration (FDA). IpsiHand developed by Neuroloutions, Inc. is indicated for rehabilitation of upper extremity chronic stroke patients. The device can be used in home and clinic settings.

Followed by IpsiHand approval in April, the USFDA has designated Blackrock Neurotech's MoveAgain Brain-Computer Interface System Receives as a Breakthrough Device for use in patients with moving disability. With this BCI system, the patient will be able to control a computer, mobile, and wheelchair.

Several such companies are actively conducting investigational studies for their BCI inventions. For instance, Neuralink the Elon Musk-run company implanted their propreitory BCI device in their first patient early this year. The PRIME study aimed to evaluate the safety and functionality of the device in patients with paralysis to control external devices with their thoughts.

These groundbreaking innovations are anticipated to revolutionize the therapy for paraplegia patients in the near future.

For instance,

Restraints

The market for BCI (brain-computer interfaces) in paraplegia is restrained by several factors such as the lack of sufficient approved products for clinical use, the high cost of approved products, high development costs, and technology ambiguity in the patient population.

Segment Analysis

The global BCI (brain-computer interfaces) in paraplegia market is segmented based on type, technology, application, and region.

Electroencephalograph (EEG) in the technology segment accounted for approximately 43.7% of the global BCI (brain-computer interfaces) in paraplegia market share

The current technology that is being widely adopted for brain-computer interface development is electroencephalography (EEG). This has become an integral technology for the BCI systems due to its non-invasive nature which collects the neural signals. Moreover, it offers a cost-effective solution for the developer and to the patient, without any devoid of accuracy.

At present, the major companies that are actively developing BCI systems are focusing on EEG technology. For instance, the FDA-approved BCI device IpsiHand, uses an EEG headset to record the brain signals and control the movement produced in devices attached to extremities. Moreover, the BCI system developed by Cognixion uses EEG as a major recording technology in their devices. The devices by EMOTIV, another leading developer in this neurotech industry are employing EEG technology. Hence, the market for this technology is anticipated to have a significant growth rate in the forecast period.

Geographical Analysis

North America is expected to dominate the market with a share of 49.5% in the global BCI (brain-computer interfaces) in paraplegia market.

The North American region is expected to dominate the market due to its well-advanced healthcare infrastructure, and higher investments by market players supported by regulatory bodies for innovations. Moreover, the approved BCI systems in the current market are only available in the region, especially in the United States. For instance, IpsiHand is currently available for U.S. citizens with moving disabilities on a prescription basis.

The Neuralink BCI system is currently being clinically evaluated in the U.S., which means, the the device if found successful, will be made available first to U.S. paraplegia patients.

In addition, as the prevalence of paralysis is higher in the U.S., the opportunity for market players to develop their innovation is also high in the region. For instance, according to a study conducted by the Christopher & Dana Reeve Foundation in 2022, approximately 17 people are suffering from some kind of stroke per 1000 population in the U.S. which makes a total prevalence of 5.78 million patients in 2023.

Hence considering all these factors, North America is expected to dominate the market and experience significant growth in the forecast period. The region also projects itself as a major hub for investments in this novel neurotech market.

Market Segmentation

By Type

• Invasive
• Minimally Invasive
• Non-Invasive

By Technology

• Microelectrode Array (MEA)
• Electrocorticography (EcoG)
• Electroencephalograph (EEG)
• Functional Near Infrared Spectroscopy (fNIRS)
• Others

By Application

• Mobility Assistance
• Communication
• Rehabilitation
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major players in the BCI (brain-computer interfaces) in paraplegia market include Neurolutions, Inc., Synchron, Neuralink, Blackrock Neurotech., BrainGate., Paradromics., Cognixion, EMOTIV, Precision Neuroscience, and Bitbrain Technologies among others.

Why Purchase the Report?

• To visualize the global BCI (brain-computer interfaces) in paraplegia market segmentation based on type, technology, application, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of BCI (brain-computer interfaces) in paraplegia market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global BCI (brain-computer interfaces) in paraplegia market report would provide approximately 62 tables, 55 figures, and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Technology
• 3.3. Snippet by Application

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising investments and R&D activities
    • 4.1.1.2. Rising technology adoption for the treatment of paraplegia
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of clinically approved devices
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Invasive*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Minimally Invasive
• 6.4. Non-Invasive

7. By Technology

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 7.1.2. Market Attractiveness Index, By Technology
• 7.2. Microelectrode Array (MEA)*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Electrocorticography (EcoG)
• 7.4. Electroencephalograph (EEG)
• 7.5. Functional Near Infrared Spectroscopy (fNIRS)
• 7.6. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Mobility Assistance*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Communication
• 8.4. Rehabilitation
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.2. Germany
    • 9.3.5.3. UK
    • 9.3.5.4. France
    • 9.3.5.5. Italy
    • 9.3.5.6. Spain
    • 9.3.5.7. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.2. Brazil
    • 9.4.5.3. Argentina
    • 9.4.5.4. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.2. China
    • 9.5.5.3. India
    • 9.5.5.4. Japan
    • 9.5.5.5. South Korea
    • 9.5.5.6. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Neurolutions, Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Synchron
• 11.3. Neuralink
• 11.4. Blackrock Neurotech.
• 11.5. BrainGate.
• 11.6. Paradromics.
• 11.7. Cognixion
• 11.8. EMOTIV
• 11.9. Precision Neuroscience
• 11.10. Bitbrain Technologies

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us